Nanotechnology-based therapeutics for targeting inflammatory lung diseases.
Nanomedicine (Lond)
; 17(12): 865-879, 2022 05.
Article
en En
| MEDLINE
| ID: mdl-35315290
Various lung diseases, including asthma, chronic obstructive pulmonary disease and pulmonary fibrosis, are associated with persistent inflammation, aberrant lung structure and consequent loss of lung function. Common treatments for inflammatory-related lung diseases rely on the use of anti-inflammatory agents to relieve symptoms and alleviate lung injury. In some severe cases, patients do not respond to anti-inflammatory agents even though larger doses have been administered. Therefore, researchers have employed a nanotechnology approach to deliver drugs in an attempt to achieve effective therapeutic outcomes. These nanoparticles, which are usually designed with a particle size <1000 nm, are formulated to deliver various drugs (i.e., corticosteroids, long-acting ß-agonists and biomacromolecules such as DNA, siRNA and mRNA) to treat inflammation-associated lung diseases. Nanoparticles can be delivered by inhalation, ingestion or injection. To date, several different nanoparticle carriers have been studied, including liposomes, solid lipid nanoparticles, polymer-based nanoparticles and dendrimers.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad Pulmonar Obstructiva Crónica
/
Enfermedades Pulmonares
Límite:
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Año:
2022
Tipo del documento:
Article
País de afiliación:
Malasia
Pais de publicación:
Reino Unido